SAMPATRILAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H40N4O9S
Molecular Weight	584.682
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)N[C@@H](CCCCN)C(=O)NC[C@H](CC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(O)=O)C(O)=O

InChI

InChIKey=LPUDGHQMOAHMMF-JBACZVJFSA-N

InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H40N4O9S
Molecular Weight	584.682
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9535199 | https://adisinsight.springer.com/drugs/800005729 | https://www.ncbi.nlm.nih.gov/pubmed/21853869

Sampatrilat (also known as UK 81252) was developed as a dual inhibitor of both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). This drug was studied for the treatment of hypertension and congestive heart failure.

Approval Year

PubMed

Title	Date	PubMed
Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat.	1996 Nov	8922744
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.	1998 Jan	9535199
Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.	2003 Apr	12649357

Patents

Sample Use Guides

In Vivo Use Guide

After a 4-week placebo run-in period, 124 patients with a mean blood pressure of 162/102 mm Hg were randomized in a double-blind parallel-group design to 1 of 5 treatments, given once daily for 10 days: 50 mg, 100 mg, or 200 mg sampatrilat

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:47:05 GMT 2025` Edited by `admin` on `Wed Apr 02 07:47:05 GMT 2025`
Record UNII	V7O29949TG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

UK-81,252

Preferred Name

English

SAMPATRILAT

Official Name

English

Sampatrilat [WHO-DD]

Common Name

English

sampatrilat [INN]

Common Name

English

N-((1-((S)-3-((S)-6-AMINO-2-METHANESULFONAMIDOHEXANAMIDO)-2-CARBOXYPROPYL)CYCLOPENTYL)CARBONYL)-L-TYROSINE

Systematic Name

English

L-TYROSINE, N2-(METHYLSULFONYL)-L-LYSYL-1-((2S)-3-AMINO-2-CARBOXYPROPYL)CYCLOPENTANECARBONYL-

Systematic Name

English

SAMPATRILAT [MI]

Common Name

English

UK-81252

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C247